Ironwood Pharmaceuticals Inc. (IRWD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ironwood Pharmaceuticals ... (IRWD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.65

-0.12 (-3.18%)

At close: Jan 14, 2025, 3:59 PM

undefined% (undefined)

Bid	3.65
Market Cap	584.90M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.01
PE Ratio (ttm)	-365.5
Forward PE	n/a
Analyst	Buy

Ask	4.19
Volume	758,692
Avg. Volume (20D)	1,898,904
Open	3.77
Previous Close	3.77
Day's Range	3.65 - 3.83
52-Week Range	3.06 - 15.70
Beta	undefined

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 3, 2010

Employees 267

Stock Exchange NASDAQ

Ticker Symbol IRWD

Website https://www.ironwoodpharma.com

Analyst Forecast

According to 4 analyst ratings, the average rating for IRWD stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 200.96% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on Feb 13, 2025, before market opens.
Analysts project revenue of $92.50M, reflecting a -21.31% YoY shrinking and earnings per share of 0.12.

Why Price Moved

2 months ago · Source

+4.8%

Ironwood Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription

5 months ago · Source

-32.61%

Ironwood Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results and revised its FY24 guidance.

News

1 month ago · businesswire.com

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wed...

2 months ago · businesswire.com

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at th...

2 months ago · zacks.com

Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down

IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024.

2 months ago · seekingalpha.com

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executi...

2 months ago · zacks.com

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

2 months ago · businesswire.com

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scienti...

2 months ago · businesswire.com

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thur...